English (UK)
中文版Vincent Liao
CR Sanjiu
Senior Investment&BD managerLily Lien
About TOT BIOPHARM International Company Limited
(HKG:1875)
TOT BIOPHARM is dedicated to developing and commercializing innovative cancer drugs and therapies, striving to build a leading brand of oncology treatments trusted by patients and their families as well as medical professionals.
The Group has in place three major integrated technology platforms:
Therapeutic Monoclonal Antibody and Antibody Drug Conjugates (ADCs) Technology Platform: it integrates research and development (R&D) and production capacities for antibody drugs and ADCs, with the designed production capacity of the commercialization base of biological drugs reaching 16,000L to accommodate high-quality commercialization of drug candidates;
Gene Engineering Based Therapeutics Technology Platform: it integrates anti-tumor immunotherapy, gene therapy and viral therapy and pursues R&D and production of tumor-targeted oncolytic virus products;
Innovative Drug Delivery Technology Platform: We have developed an innovative drug delivery system, including an advanced targeted liposome drug delivery system.
Using these platforms, the Group has studied and developed various anti-tumor drug series, and formed a high quality and comprehensive drug product chain. Currently, the Group has 12 drugs under research and development. On top of developing innovative proprietary drugs, TOT BIOPHARM also draws on its own industry value chain to build a complete industry chain platform that supports from R&D, clinical development to production and marketing. By adopting an open platform business model, it is able to cooperate with biomedical enterprises and third parties in different stages along its industry value chain.
TOT BIOPHARM
DirectorDon Lin
Guoqian Medical has two business platforms: Guoqian Venture Capital and Guoqian Medical Technology Innovation Research Institute.
Guoqian Venture Capital is a professional and market-oriented venture capital institution that focuses on equity investment in early innovation and entrepreneurship projects in the fields of medical devices, in vitro diagnostic reagents and biotechnology. Focusing on high-end scientific and technological talents with Chinese major talent engineering experts as the core, they seek high-quality investment targets during the transformation of scientific and technological achievements, the introduction of technological projects, the evaluation of innovative and entrepreneurial projects, and the landing of innovative and entrepreneurial projects.
Guoqian Medical Technology Innovation Research Institute is committed to cultivating cutting-edge technologies and projects in the domestic medical device industry, and providing it with multi-faceted technologies, policies, talents, industrialization and markets through direct investment, entrepreneurial services, and scientific and technological achievement transformation services. Integration of services and resources to create an innovative platform for national technological innovation and industrial integration and empowerment. At the same time, it has also become an enabling platform for post-investment enterprises of Guoqian Fund. By creating industrial clusters and industrial ecology, it will provide post-investment management, post-investment services, and post-investment empowerment to post-investment enterprises.
Based on the business philosophy of “achieving the dreams of others”, Guoqian Medical uses market-oriented and specialized equity investment funds to create industrial agglomeration and industrial ecology; it empowers post-investment enterprises by creating industrial agglomeration and industrial ecology. The two platforms complement each other, and strive to build a medical device industry cluster and ecosystem in Suzhou High-tech Zone in 10 years, becoming one of the main promoters of the domestic medical device industry.
Responsive Web Design powered by 